Abstract
BackgroundPhase III randomised controlled trials (BLISS 52 and 76) in patients with systemic lupus erythematosus (SLE) have established the efficacy and safety of belimumab plus standard SLE therapy (SoC) vs...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have